VIDEO: Vonoprazan-based regimens superior to standard for H. pylori eradication
Click Here to Manage Email Alerts
In this video exclusive, William D. Chey, MD, from the University of Michigan, discussed results from a pivotal phase 3 trial of vonoprazan in Helicobacter pylori infection.
Chey and colleagues studied vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) and vonoprazan combined with amoxicillin (vonoprazan dual therapy) vs. lansoprazole combined with amoxicillin and clarithromycin (lansoprazole triple therapy).
Chey noted both vonoprazan-based treatment regimens showed superior eradication rates compared with the standard of care lansoprazole triple therapy.
According to Chey, both vonoprazan-based regimens successfully met the primary endpoints, which were non-inferiority of the H. pylori eradication rate. The secondary endpoints were also met by both the vonoprazan triple therapy and vonoprazan dual therapy. Both therapies demonstrated superior eradication rates compared with the lansoprazole triple therapy among all patients and patients with clarithromycin resistant strains of H. pylori.
The vonoprazan-based regimens were generally well tolerated with a safety profile like lansoprazole triple therapy, according to Chey.
“These are new regimens that are exciting and more effective than our current standard,” Chey said.
Collapse
Read more about
Click Here to Manage Email Alerts